KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Thermo Fisher Scientific (TMO) over the last 17 years, with Q3 2025 value amounting to $404.0 million.

  • Thermo Fisher Scientific's Capital Expenditures rose 4852.94% to $404.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 1622.64%. This contributed to the annual value of $1.4 billion for FY2024, which is 534.14% down from last year.
  • According to the latest figures from Q3 2025, Thermo Fisher Scientific's Capital Expenditures is $404.0 million, which was up 4852.94% from $294.0 million recorded in Q2 2025.
  • Thermo Fisher Scientific's 5-year Capital Expenditures high stood at $831.0 million for Q4 2021, and its period low was $272.0 million during Q3 2024.
  • Its 5-year average for Capital Expenditures is $458.2 million, with a median of $458.0 million in 2023.
  • In the last 5 years, Thermo Fisher Scientific's Capital Expenditures surged by 14822.13% in 2021 and then plummeted by 4387.35% in 2023.
  • Thermo Fisher Scientific's Capital Expenditures (Quarter) stood at $831.0 million in 2021, then tumbled by 33.81% to $550.0 million in 2022, then decreased by 26.36% to $405.0 million in 2023, then rose by 18.52% to $480.0 million in 2024, then decreased by 15.83% to $404.0 million in 2025.
  • Its Capital Expenditures stands at $404.0 million for Q3 2025, versus $294.0 million for Q2 2025 and $362.0 million for Q1 2025.